Harrow (NASDAQ:HROW) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Harrow (NASDAQ:HROW) posted its earnings results on Thursday. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million.

Harrow Trading Down 6.0 %

Shares of NASDAQ:HROW opened at $26.21 on Friday. The stock has a market capitalization of $933.47 million, a price-to-earnings ratio of -27.88 and a beta of 0.69. Harrow has a 1-year low of $9.86 and a 1-year high of $59.23. The company has a 50 day moving average price of $28.90 and a 200 day moving average price of $38.01. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HROW. B. Riley reduced their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Harrow in a research note on Tuesday, March 18th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.